Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix Hexa Immunogenicity and Safety in Healthy Infants
NCT00753649Phase 4Completed
- Sponsor
- GSK
- Start
- Sep 2008
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertussis filamentous haemagglutinin in hepatitis B (HBV), Tetanus, poliomyelitis and 3 more (2 arms), sponsored by GSK. Primary endpoint: Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP). Started Sep 2008; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
hepatitis B (HBV)TetanuspoliomyelitisdiphtheriaHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00753649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753649.